AN2 Therapeutics, Inc. (ANTX)

US — Healthcare Sector
Peers: AVTE  ADAG  ACRV  RZLT  ANEB  MLYS  MOLN  PHVS  PEPG  PMVP  ELYM  MNOV 

Automate Your Wheel Strategy on ANTX

With Tiblio's Option Bot, you can configure your own wheel strategy including ANTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANTX
  • Rev/Share 0.0
  • Book/Share 2.4399
  • PB 0.4959
  • Debt/Equity 0.0
  • CurrentRatio 8.6797
  • ROIC -0.6823

 

  • MktCap 36512621.0
  • FreeCF/Share -1.4071
  • PFCF -0.8634
  • PE -0.8018
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.5317

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About AN2 Therapeutics, Inc. (ANTX)

  • IPO Date 2022-03-25
  • Website https://www.an2therapeutics.com
  • Industry Biotechnology
  • CEO Mr. Eric E. Easom
  • Employees 22
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.